Insider Trading March 24, 2026

BCP Director Adds to Stake as Shares Hover Near 52-Week Low

George Grunebaum buys 6,800 BCP Investment Corp shares; firm posts mixed fourth-quarter results and receives analyst price-target cut

By Leila Farooq BCIC
BCP Director Adds to Stake as Shares Hover Near 52-Week Low
BCIC

A director of BCP Investment Corp increased his holding by 6,800 common shares on March 23, 2026, buying at $7.5399 per share for a total of $51,271. The purchase comes while BCIC shares are trading near their 52-week low and after the company reported fourth-quarter 2025 results that beat EPS and revenue estimates but presented mixed underlying metrics that prompted a lower price target from an analyst.

Key Points

  • Director George Grunebaum bought 6,800 BCP Investment Corp shares on March 23, 2026 at $7.5399 each, totaling $51,271, and now directly owns 14,136 shares.
  • BCIC shares trade at $7.48, close to a 52-week low of $7.15, with a 10% decline over the prior week; InvestingPro Tips labels the stock oversold and reports a 21.75% dividend yield.
  • BCP reported Q4 2025 EPS of $0.57 and revenue of $17.5 million, both above analysts' expectations, but Keefe, Bruyette & Woods cut its price target from $14.00 to $9.00 while keeping a Market Perform rating.

Transaction details

Director George Grunebaum purchased 6,800 shares of common stock of BCP Investment Corp (NASDAQ:BCIC) on March 23, 2026. The shares were bought at a price of $7.5399 each, bringing the aggregate cost of the purchase to $51,271. Following this acquisition, Grunebaum now directly holds 14,136 shares of BCP Investment Corp.


Market context and valuation notes

At the time of reporting, BCIC shares are trading at $7.48, which places the stock close to its 52-week low of $7.15 and reflects a 10% decline over the past week. According to InvestingPro Tips, the stock is currently in oversold territory and the shares offer a dividend yield of 21.75%.

Investors seeking further valuation detail are directed to the InvestingPro Pro Research Report, which contains additional ProTips and deeper analysis of BCIC’s valuation metrics.


Recent financial performance

BCP Investment Corporation released its fourth-quarter 2025 results reporting an earnings per share (EPS) of $0.57, exceeding the analyst projection of $0.5325 by 7.04%. The company also reported revenue of $17.5 million, higher than the expected $16.98 million.

Despite the headline beats on EPS and revenue, an analyst at Keefe, Bruyette & Woods reduced the firm’s price target for BCIC shares from $14.00 to $9.00 while maintaining a Market Perform rating. The firm cited a challenging quarter in which net investment income missed expectations and the company posted a 7% operating return on equity. The company’s net asset value declined by 5% during the quarter.


What this means for investors

The insider purchase increases a director’s direct ownership and occurs against a backdrop of near-term share-price weakness and a steep dividend yield. The quarter’s reported EPS and revenue came in above consensus, but the analyst reaction underscores continuing concerns around core investment income, return on equity and a fall in net asset value.

Readers who want the full set of valuation tools and additional ProTips can consult the InvestingPro Pro Research Report referenced above for more granular analysis.


Summary

George Grunebaum acquired 6,800 BCIC shares on March 23, 2026 at $7.5399, increasing his direct stake to 14,136 shares. The purchase took place while the stock traded near its 52-week low and after BCP Investment reported fourth-quarter 2025 results that beat EPS and revenue estimates but presented mixed underlying metrics. Keefe, Bruyette & Woods lowered its price target from $14.00 to $9.00 and maintained a Market Perform rating, citing missed net investment income expectations, a 7% operating return on equity and a 5% decline in net asset value.

Risks

  • Share-price pressure and recent volatility - BCIC is trading near its 52-week low and declined 10% over the past week, indicating short-term downside risk to investors.
  • Operational and income variability - the quarter featured net investment income that missed expectations and a 7% operating return on equity, a concern cited by the analyst.
  • Net asset value contraction - the company’s net asset value fell 5% during the quarter, reflecting potential valuation and balance-sheet pressures.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026